Clinical trials: Avian Influenza
Influenza
Dose-escalation Study of Single Dose GHB04L1 in Healthy Adults
It is the hypothesis of this study that intranasal vaccination with a single dose of GHB04L1 is safe and induces an immune response against influenza A H5N1.
- Trial name
- GHB-CS03 (NCT00741806)
- Testing
- GHB04L1
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Acute Lung Injury, Acute Respiratory Distress Syndrome (ARDS)
Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection
The purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome (ARDS), Multiple Organ Failure
- Trial name
- NCT02095444
- Testing
- Menstrual blood stem cells
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- S-Evans Biosciences Co., Ltd.
Influenza, Influenza Vaccines
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
- Trial name
- NCT01788228
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-339851 in healthy subjects.
- Trial name
- NCT03345043
- Testing
- VAL-339851
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
H5N1 Influenza
H5N1 Vaccine Study in Japanese Adults
The purpose of this study is to obtain immunogenicity and safety data of two different dose levels of an H5N1 pandemic influenza vaccine in a healthy Japanese adult population aged 18 to 59 years.
- Trial name
- NCT01382329
- Testing
- H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)
- Where
- 3 sites in Japan
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Orthomyxoviridae Infections
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pandemic influenza vaccine, efforts to develop a lower antigen dose formulation with improved immunogenicity using adjuvants were initiated.
- Trial name
- NCT00664417
- Testing
- Monovalent subvirion H5N1 influenza vaccine, Physiological saline
- Where
- 6 sites in United States
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged >=18 years.
- Trial name
- NCT00719043
- Testing
- A/turkey H5N1 vaccine, Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- Where
- 13 sites in United States, Canada
- Volunteers
- 841 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bird Flu, Avian Influenza
A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
The focus of this study is to evaluate the safety, reactogenicity and humoral immune responses of the study vaccine when administered at the dose of 7.5 µg HA, 15 µg HA, or 30 µg HA to human subjects.
- Conditions
- Bird Flu, Avian Influenza, Influenza A(H5N1)
- Trial name
- NCT01675284
- Testing
- AT-301
- Where
- Taiwan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medigen Biotechnology Corporation
Influenza
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers
The purpose of this study is to evaluate the immunogenicity and safety of the investigational vaccine in the subjects during their participation in the study.
- Trial name
- NCT01987011
- Testing
- MG1109
- Where
- 4 sites in South Korea
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Children
A single center, stratified, randomized and double-blind phase II clinical trial was conducted in children to evaluate the safety and immunogenicity of an split-virion pandemic influenza A vaccine (H5N1).
- Trial name
- NCT00900991
- Testing
- split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
H7N9 Influenza
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults between the ages of 18 years and 65 years.
- Trial name
- NCT01928472
- Testing
- H7N9c low dose with adjuvant, H7N9c medium dose with adjuvant, H7N9c high dose with adjuvant
- Where
- 6 sites in United States
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children
The objective of the study is to evaluate the immunogenicity and safety of prime-boost vaccination schedule of GSK Biologicals' investigational vaccine GSK1562902A.
- Trial name
- NCT01323946
- Testing
- GSK Biologicals' investigational vaccine GSK1562902A
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
This study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of FLUAD-H5N1 vaccine compared to 2 doses of trivalent, interpandemic FLUAD, each administered 3 weeks apart.
- Trial name
- NCT00434733
- Testing
- Pandemic influenza vaccine
- Where
- Poland
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Novartis
H7N9 Influenza Vaccine
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.
- Trial name
- NCT02436928
- Testing
- AT-501 High Dose vaccine, AT-501 High Dose vaccine with Adjuvant, AT-501 Low Dose vaccine
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Avian Influenza, Bird Flu
Safety Study of an Oral Vaccine to Prevent Avian Influenza
The purpose of this study is to demonstrate the safety and immunogenicity of an oral vaccine to prevent avian influenza. Volunteers will receive either one or two doses of research vaccine or placebo as part of this study.
- Trial name
- H5N1 (NCT01335347)
- Testing
- ND1.1
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Vaxart
Influenza, Pandemic Influenza
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
The objectives of this study are to assess the dose-related safety and immunogenicity of six different dose levels of inactivated, Vero cell-derived reverse genetic reassortant A/H5N1/Indonesia/05/2005 influenza vaccine in a…
- Trial name
- NCT00783926
- Testing
- H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)
- Where
- 6 sites in United States
- Volunteers
- 422 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older
The purpose of this study is to obtain immunogenicity and safety data of an H5N1 pandemic influenza vaccine in a Japanese elderly population aged 65 years and older.
- Trial name
- NCT01774032
- Testing
- H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
- Where
- 2 sites in Japan
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.